Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sonnet BioTherapeutics Holdings (SONN) has shared an announcement.
The Company has partnered with the Sarcoma Oncology Center to further the development of SON-1210—a promising new drug for solid tumor immunotherapy, focusing on pancreatic cancer. The drug, hailed for its preclinical success and lack of severe toxicity, will undergo a Phase 1/2a clinical study to assess its efficacy in combination with approved chemotherapy agents. This study underscores the Company’s commitment to addressing the urgent need for effective pancreatic cancer treatments, with forward-looking statements suggesting a positive outlook for its clinical and commercial potential.
For an in-depth examination of SONN stock, go to TipRanks’ Stock Analysis page.